Wollina Uwe, Pabst Friedemann, Kuss Heidrun, Tilp Michaela, Runge Juliane
Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
J Clin Aesthet Dermatol. 2013 May;6(5):45-8.
Mucous membrane pemphigoid is a rare blistering autoimmune disorder that can lead to significant disability. Recently, the monoclonal anti-CD20 antibody rituximab has shown efficacy in pemphigus and pemphigoid, but the data for pemphigoid are relatively sparse. The authors report a series of four patients with severe cicatrical pemphigoid treated with rituximab. All of these patients responded and two of them had a complete remission. Rituximab is a second-line treatment for severe and recalcitrant cicatrical pemphigoid.
黏膜类天疱疮是一种罕见的水疱性自身免疫性疾病，可导致严重残疾。最近，单克隆抗CD20抗体利妥昔单抗已显示出对天疱疮和类天疱疮有效，但关于类天疱疮的数据相对较少。作者报告了一组接受利妥昔单抗治疗的4例重度瘢痕性类天疱疮患者。所有这些患者均有反应，其中2例完全缓解。利妥昔单抗是重度和顽固性瘢痕性类天疱疮的二线治疗药物。
